Compare Crispr Therapeutics AG (CRSP) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vale SA — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Vale SA trades at $13.62 (market cap $57.32B). The key difference: Vale SA is far larger — about 11.7× Crispr Therapeutics AG's market cap, and Vale SA pays a 8.87% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vale SA for 109 Days on average.
| CRSP | VALE | |
|---|---|---|
Market Cap | $4.88B | $57.32B |
Volume | 2,861,747 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $73.97 | $17.82 |
52-Week Low | $44.34 | $10.75 |
Typical Hold Time | 77 Days | 109 Days |
Enterprise Value | $3.30B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
VALE stock trades at $13.42, down 1.4% on the day, reflecting recent pressure from earnings misses and sector-wide declines in steel producers. The technical outlook is bearish, with price near key support at $13, while fundamentals show declining net income margins and profit compression amid rising costs. Recent news highlights concerns over iron ore pricing and U.S. steel expansion plans impacting sentiment.
The investment case is mixed: analyst consensus leans Hold with a $16.21 price target, suggesting modest upside, but risks include cyclical commodity exposure, Brazilian regulatory issues, and margin pressure. Base metals growth offers a partial offset, but earnings consistency remains a challenge for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
